发布: 2017年12月05日第7卷第23期 DOI: 10.21769/BioProtoc.2627 浏览次数: 8989
Abstract
Various genetic alterations such as chromosomal translocation cause leukemia. For examples, gene rearrangements of the mixed-lineage leukemia (MLL) gene generate MLL fusion genes, whose products are potent oncogenic drivers in acute leukemia. To better understand the mechanism of disease onset, several murine leukemia models using retroviral gene transduction, xenograft, or Cre-mediated chromosomal translocation have been developed over the past twenty years. Particularly, a retroviral gene transduction-mediated murine leukemia model has been frequently used in the leukemia research field. Here, we describe the detailed protocol for this model.
Keywords: Mixed lineage leukemia (混合细胞系白血病)Background
Gene rearrangements generate mixed-lineage leukemia (MLL) fusion genes, which cause highly aggressive acute leukemia. MLL-rearrangements are often associated with few additional genetic alterations and poor clinical outcomes (Andersson et al., 2015). Wild-type MLL enhances and maintains the expression of a subset of genes, including homeobox (Hox) genes, to stimulate the expansion of immature progenitors (Jude et al., 2007). The expression of Hoxa9 and Meis1 is highest in the immature progenitor/stem cell fraction, but gradually declines as cells differentiate, and eventually diminishes in terminally-differentiated cell fractions (Somervaille and Cleary, 2006; Yokoyama et al., 2013). The MLL fusion protein constitutively up-regulates the expression of target genes, including Hoxa9 and Meis1, to immortalize immature progenitor cells and cause leukemia in vivo (Ayton and Cleary, 2003; Lavau et al., 1997). To date, more than 130 different MLL-rearrangements have been identified (Meyer et al., 2017). Two-thirds of MLL-rearranged leukemia cases are caused by fusion with a gene that is part of the AF4 family-ENL family-P-TEFb (AEP) complex (Yokoyama et al., 2010). The MLL fusion proteins constitutively form an MLL/AEP hybrid complex on the target chromatin (Okuda et al., 2014; Yokoyama et al., 2010), which further associates with the SL1 complex to activate RNA polymerase II-dependent transcription (Okuda et al., 2015 and 2016). AEP-mediated transactivation of MLL target genes transformed myeloid progenitors ex vivo, but did not cause leukemia in vivo, which suggested that other function is additionally required for in vivo leukemogenesis (Okuda et al., 2017). Recently, we showed that the ability to recruit the DOT1L complex is necessary to cause leukemia in vivo in addition to the ability to recruit AEP using in vivo leukemogenesis model. Thus, the combinatorial use of the in vivo leukemogenesis model and myeloid progenitor transformation assay is necessary to dissect the functional properties of oncogenes. In this protocol, we describe the in vivo leukemogenesis model using retroviral transduction in detail.
Materials and Reagents
Equipment
Software
Procedure
文章信息
版权信息
© 2017 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Okuda, H. and Yokoyama, A. (2017). In vivo Leukemogenesis Model Using Retrovirus Transduction. Bio-protocol 7(23): e2627. DOI: 10.21769/BioProtoc.2627.
分类
癌症生物学 > 通用技术 > 动物模型
细胞生物学 > 细胞分离和培养 > 转化
癌症生物学 > 瘤形成 > 白血病生成
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link